ロード中...
Immune checkpoint inhibitors in challenging populations
Immune checkpoint inhibitors, including those targeting the PD-1/PD-L1 and CTLA-4 pathways, are revolutionizing cancer therapeutics. Both activity and toxicities largely stem from unleashing tumor- or host-specific cytotoxic T cells. Many patients seen in routine clinical practice did not qualify fo...
保存先:
| 出版年: | Cancer |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5445005/ https://ncbi.nlm.nih.gov/pubmed/28241095 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30642 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|